AbCellera Biologics Inc. (ABCL) AI Stock Analysis
ABCL AI stock analysis summary
AI ResearchAbCellera Biologics Inc. (ABCL) is an antibody discovery and development platform company partnering with biopharmaceutical firms, including Eli Lilly and Company. Over the trailing twelve months, revenue was $66.2M with a net loss per share of -$0.54. The company maintains a solid balance sheet with $404.5M in net cash as of June 30, 2026.
- Market cap
- $3.82B
- Revenue (TTM)
- $66.2M
- P/E
- — fwd 27.5x
- 1Y return
- 102.1% S&P 500 16.8%
- Avg. target
- $16.82 42.5% vs last close
Bull case
- AbCellera held $540.1M in cash and short-term investments with a net cash position of $404.5M as of June 30, 2026.
- Wall Street analysts project an average price target of $16.82, implying 42.5% upside from the recent close of $11.80.
- The stock demonstrated strong momentum with a 1-year return of 102.1% and a year-to-date return of 245.0%.
Bear case
- Revenue has contracted at a 5-year CAGR of -20.3%, and consensus revenue estimates for FY2026 are just $26.4M.
- Free cash flow remained deeply negative at -$174.1M in FY2025 alongside a net loss of -$146.4M.
- The stock trades at an elevated price-to-sales multiple of 57.8x, significantly higher than the peer median of 4.1x.
What AbCellera Biologics does
AbCellera Biologics Inc. operates as an innovator in antibody drug discovery and development. Founded in 2012 and based in Vancouver, Canada, the company pioneered a platform designed to accelerate therapeutic antibody identification. It uses proprietary technologies to uncover pre-enriched antibodies derived from natural immune responses to enhance the efficiency of drug discovery. AbCellera maintains a portfolio of discovery programs spanning various stages, including completed initiatives, ongoing projects, and collaborations. It also collaborates extensively with Eli Lilly and Company under a comprehensive research collaboration and license agreement to advance antibody-based therapeutics.
Growth and profitability
Annual revenue fluctuated widely from $11.6M in FY2021 to a peak of $485.4M in FY2022, before dropping to $38.0M in FY2023, $28.8M in FY2024, and rising to $75.1M in FY2025. Across the 5-year span from FY2020 to FY2025, revenue posted a CAGR of -20.3%. In FY2025, net income was -$146.4M with a net margin of -194.9% and R&D expense of $186.8M. For the latest quarter ended June 30, 2026, quarterly revenue fell 76.3% year-over-year, while quarterly earnings grew 45.9%. Operating cash flow was -$131.3M and free cash flow was -$174.1M in FY2025.
Balance sheet and cash flow
As of June 30, 2026, AbCellera held $540.1M in cash and short-term investments against $135.6M in total debt, yielding net cash of $404.5M. Total assets stood at $1.31B and shareholders' equity was $896.0M. The company shows a debt-to-equity ratio of 0.15 and a current ratio of 12.77. In FY2025, capital expenditures totaled $42.8M, while its share count fell 3.0% over five years.
Valuation and performance
With a market cap of $3.82B and an enterprise value of $3.59B, ABCL trades at a price-to-sales ratio of 57.8x, compared to 4.1x for the median of its US-listed Healthcare peers. Its forward P/E ratio is 27.5x, above the peer median of 17.3x, while its EV-to-EBITDA stands at 5.3x versus the peer median of 12.0x. Over the past year, ABCL gained 102.1%, outperforming the S&P 500 (SPY) return of 16.8%, but its 5-year return of -24.0% trailed the S&P 500 return of 83.0%.
What analysts expect
Wall Street analysts hold 9 Strong Buy, 2 Buy, and 1 Hold ratings, with 0 Sell or Strong Sell ratings. The mean price target is $16.82, representing a 42.5% premium to the last close of $11.80 on October 16, 2026. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $26.4M and EPS of -$0.67. AbCellera beat EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 9, 2026.
Key risks and what to watch
- In the latest quarter ended June 30, 2026, revenue dropped 76.3% year-over-year, illustrating revenue volatility.
- Operating cash flow was negative at -$131.3M in FY2025, which could deplete cash reserves if sustained.
- Short interest stands at 12.8% of float, which reflects negative sentiment in the market.
- With a beta of 1.41, the stock exhibits higher volatility than the broader equity market.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this ABCL AI stock analysis
This page is an AI-written research summary of AbCellera Biologics Inc. (ABCL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: ABCL income statement, ABCL balance sheet, ABCL key metrics, ABCL analyst forecast, ABCL chart. See the ABCL stock overview for the latest quote and news.
ABCL AI stock analysis FAQ
What does AbCellera Biologics do?
AbCellera Biologics discovers and develops therapeutic antibodies using a proprietary platform that analyzes natural immune responses. It conducts discovery programs independently and in partnerships, such as with Eli Lilly and Company.
Does AbCellera Biologics pay a dividend?
No, AbCellera does not pay a dividend.
What is AbCellera's cash position?
As of June 30, 2026, AbCellera held $540.1M in cash and short-term investments and $135.6M in total debt, leaving net cash of $404.5M.
When is AbCellera's next earnings report?
AbCellera's next scheduled earnings date is November 9, 2026.